{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:08:26Z","timestamp":1781248106857,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117193","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T09:07:35Z","timestamp":1735031255000},"page":"117193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity"],"prefix":"10.1016","volume":"284","author":[{"given":"Shuxia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-6677","authenticated-orcid":false,"given":"Zhiqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-1606","authenticated-orcid":false,"given":"Chang-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117193_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117193_bib2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/med.21859","article-title":"Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives","volume":"42","author":"Feng","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.117193_bib3","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1128\/MCB.22.18.6509-6520.2002","article-title":"A mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase","volume":"22","author":"Maruyama","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.117193_bib4","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117193_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117193_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112426","article-title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery","volume":"200","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib8","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1021\/acs.jmedchem.3c01028","article-title":"Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of inflammatory diseases","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117193_bib10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.117193_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.117193_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117193_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.117193_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12038-016-9600-6","article-title":"Bromodomain and extra-terminal (BET) family proteins: new therapeutic targets in major diseases","volume":"41","author":"Padmanabhan","year":"2016","journal-title":"J. Biosci."},{"key":"10.1016\/j.ejmech.2024.117193_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00007-17","article-title":"BRD4 couples NF-\u03baB\/RelA with airway inflammation and the IRF-RIG-I amplification loop in respiratory syncytial virus infection","volume":"91","author":"Tian","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2024.117193_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.117193_bib17","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2174\/1574885514666190618113519","article-title":"Bromodomain-containing protein 4: a druggable target","volume":"20","author":"Shi","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2024.117193_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2018.12.012","article-title":"Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma","volume":"445","author":"Han","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.117193_bib19","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.117193_bib20","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting bromodomain and extraterminal proteins for drug discovery: from current progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/13543776.2020.1702645","article-title":"A patent review of BRD4 inhibitors (2013-2019), Expert Opin","volume":"30","author":"Lu","year":"2020","journal-title":"Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.117193_bib22","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains","volume":"56","author":"Mirguet","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib23","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.18632\/oncotarget.13814","article-title":"The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus","volume":"8","author":"V\u00e1zquez","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.117193_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.117193_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117193_bib26","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/med.21942","article-title":"Recent progress and structural analyses of domain-selective BET inhibitors","volume":"43","author":"Divakaran","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.117193_bib28","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/acs.jmedchem.1c01851","article-title":"Discovery, X-ray crystallography, and anti-inflammatory activity of bromodomain-containing protein 4 (BRD4) BD1 inhibitors targeting a distinct new binding site","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","article-title":"Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation","volume":"151","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.celrep.2018.03.106","article-title":"Selective antagonists of the bronchiolar epithelial NF-\u03baB-bromodomain-containing protein 4 pathway in viral-induced airway inflammation","volume":"23","author":"Tian","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.117193_bib31","doi-asserted-by":"crossref","first-page":"11080","DOI":"10.1021\/acs.jmedchem.9b01010","article-title":"Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as bromodomain and extra-terminal Domain (BET) inhibitors with selectivity for the first bromodomain with potential high efficiency against acute gouty arthritis","volume":"62","author":"Jiang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176382","article-title":"NHWD-870, can downregulate dendritic cells maturation via the IRF7-mediated signaling pathway to ameliorate imiquimod-induced psoriasis-like murine skin inflammation","volume":"968","author":"Jin","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117193_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cell.2009.05.047","article-title":"Control of inducible gene expression by signal-dependent transcriptional elongation","volume":"138","author":"Hargreaves","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117193_bib34","doi-asserted-by":"crossref","first-page":"E3993","DOI":"10.1073\/pnas.1700109114","article-title":"BRD4 modulates the innate immune response through Mnk2-eIF4E pathway-dependent translational control of I\u03baB\u03b1","volume":"114","author":"Bao","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.117193_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095051","article-title":"Brd4 is essential for IL-1\u03b2-induced inflammation in human airway epithelial cells","volume":"9","author":"Khan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.117193_bib36","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1039\/C8OB00624E","article-title":"Regioselective synthesis and biological evaluation of N-substituted 2-aminoquinazolin-4-ones","volume":"16","author":"Liao","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib37","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/molecules28030978","article-title":"Quinazolinones, the winning horse in drug discovery","volume":"28","author":"Alsibaee","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.117193_bib38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s42995-021-00101-2","article-title":"The intriguing chemistry and biology of sulfur-containing natural products from marine microorganisms (1987-2020), Mar","volume":"3","author":"Hai","year":"2021","journal-title":"Life Sci. Technol."},{"key":"10.1016\/j.ejmech.2024.117193_bib39","doi-asserted-by":"crossref","first-page":"11395","DOI":"10.1021\/acs.jmedchem.1c00734","article-title":"Amphipathic barbiturates as mimics of antimicrobial peptides and the marine natural products eusynstyelamides with activity against multi-resistant clinical isolates","volume":"64","author":"Paulsen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s42995-022-00162-x","article-title":"Identification of marine natural product Pretrichodermamide B as a STAT3 inhibitor for efficient anticancer therapy","volume":"5","author":"Li","year":"2023","journal-title":"Mar. Life Sci. Technol."},{"key":"10.1016\/j.ejmech.2024.117193_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s42995-020-00077-5","article-title":"Co-culture: stimulate the metabolic potential and explore the molecular diversity of natural products from microorganisms, Mar","volume":"3","author":"Peng","year":"2021","journal-title":"Life Sci. Technol."},{"key":"10.1016\/j.ejmech.2024.117193_bib42","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/np200037z","article-title":"Triazole and dihydroimidazole alkaloids from the marine sediment-derived fungus Penicillium paneum SD-44","volume":"74","author":"Li","year":"2011","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2024.117193_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114423","article-title":"Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5- carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis","volume":"238","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116272","article-title":"Total synthesis and structural modification of the dibenzylbutane lignan LCA as a potent anti-inflammatory agent against LPS-induced acute lung injury","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/ol303331g","article-title":"Direct one-pot synthesis of luotonin F and analogues via rational logical design","volume":"15","author":"Zhu","year":"2013","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2024.117193_bib46","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41598-022-05698-7","article-title":"Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation","volume":"12","author":"Kumbhar","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.117193_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/1570180819666220805163725","article-title":"Molecular docking and simulation binding analysis of boeravinone B with caspase-3 and EGFR of hepatocellular carcinoma","volume":"20","author":"Krishnamoorthy","year":"2023","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2024.117193_bib48","doi-asserted-by":"crossref","first-page":"8725","DOI":"10.1021\/acs.jmedchem.3c00372","article-title":"Discovery of 1H-imidazo[4,5-b]pyridine derivatives as potent and selective BET inhibitors for the management of neuropathic pain","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib49","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/acs.jmedchem.3c02104","article-title":"Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117193_bib50","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/acs.jmedchem.2c00100","article-title":"Structure-based discovery and optimization of furo[3,2-c]pyridin-4(5H)-one derivatives as potent and second bromodomain (BD2)-selective bromo and extra terminal domain (BET) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:23:17Z","timestamp":1751386997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"alternative-id":["S0223523424010754"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117193","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117193"}}